BioPharmSignal logoBioPharmSignal

Biotech News

Shattuck Labs Announces Two Poster Presentations at UEG Week 2026

Shattuck Labs (STTK)Shattuck LabsConference / presentation

AUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced two upcoming poster presentations at United European Gastroenterology (UEG) Week 2026, taking place October 17–20, 2026, in Barcelona, Spain.

Related news

ELVNEnliven Therapeutics2026-08-31 22:05 EST

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

STTKShattuck Labs2026-10-01 11:00 EST

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

STTKShattuck Labs2026-09-02 20:05 EST

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

ZNTLZentalis2026-10-18 22:05 EST

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

CHRSCoherus BioSciences, Inc.2026-10-14 20:30 EST

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

BMEABiomea Fusion2026-10-12 20:30 EST

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

LYELLyell Immunopharma2026-09-14 11:00 EST

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

MGNXMacroGenics2026-09-09 20:05 EST

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

FATEFate Therapeutics2026-09-09 11:00 EST

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

MDXGMiMedx2026-09-08 12:00 EST

MIMEDX to Participate in Upcoming Investor Conferences

View all latest news

Shattuck Labs

Immune-Mediated Diseases Shattuck Labs develops antibodies for inflammatory and immune-mediated diseases. Its current strategy centers on blocking death receptor 3, a regulator of activated immune cells. SL-325 SL-325 is a monoclonal antibody targeting DR3. The candidate has completed enrollment in a Phase 1 single- and...

Recent company news

STTKShattuck Labs2026-10-13 12:00 EST

Shattuck Labs Announces Two Poster Presentations at UEG Week 2026

STTKShattuck Labs2026-10-01 11:00 EST

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

STTKShattuck Labs2026-09-02 20:05 EST

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

STTKShattuck Labs2026-08-11 10:15 EST

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

STTKShattuck Labs2026-06-10 04:21 EST

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

Stock data

Close
5.58 USD
Market cap
373.43M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States